AR048241A1 - Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c . - Google Patents
Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c .Info
- Publication number
- AR048241A1 AR048241A1 ARP050100679A ARP050100679A AR048241A1 AR 048241 A1 AR048241 A1 AR 048241A1 AR P050100679 A ARP050100679 A AR P050100679A AR P050100679 A ARP050100679 A AR P050100679A AR 048241 A1 AR048241 A1 AR 048241A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocyclyl
- heteroaryl
- aryl
- cycloalkyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
La presente trata de compuestos azufrados como inhibidores de la serina proteasa NS3 del virus de la hepatitis C, composiciones farmacéuticas que los contienen, usos y métodos de preparacion. Reivindicacion 1: Un compuesto, o enantiomeros, estereoisomeros, rotámeros, tautomeros y racematos de dicho compuesto, o una sal o solvato o éster aceptables desde el punto de vista farmacéutico de dicho compuesto, teniendo dicho compuesto la estructura general que se muestra en la formula (1): en la cual: R1 es H, OR8, NR9R10, o CHR9R10, en los cuales R8, R9, y R10 pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo formado por: H, alquilo, alquenilo-, alquinilo-, arilo-, heteroalquilo-, heteroarilo- , cicloalquilo-, heterociclilo-, arilalquilo- y heteroarilalquilo; A y M pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente e R, OR, NHR, NRR', SR, SO2R y halo; o A y M están conectados uno al otro de modo tal que el resto de formula (2) que se mostro anteriormente en la formula (1) forma tanto un cicloalquilo de tres, cuatro, seis, siete y ocho miembros, un heterociclilo de cuatro a ocho miembros, un arilo de seis a diez miembros, o un heteroarilo de cinco a diez miembros; E es C(H) o C( R ); L es C(H), C( R ), CH2C( R ), o C( R )CH2; R, R', R2 y R3 pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo formado por H, alquilo, heteroalquilo, alquenilo, heteroalquenilo, alquinilo, heteroalquinilo, cicloalquilo, heterociclilo, arilo, arilalquilo, heteroarilo, y heteroarilalquilo, o alternativamente R y R' en NRR' están conectados uno al otro e manera tal que NRR' forma un heterociclilo de cuatro a ocho miembros; e Y se selecciona de los siguientes restos de formulas (3), en los cuales G es NH u O; y R15, R16, R17 y R18 pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo formado por H, alquilo, heteroalquilo, alquenilo, heteroalquenilo, alquinilo, heteroalquinilo, cicloalquilo, heterociclilo, arilo, y heteroarilo, o alternativamente, (i) R15 y R16 están conectados entre sí para formar una estructura cíclica de cuatro a ocho miembros, y (ii) del mismo modo, en forma independiente R17 y R18 están conectados uno al otro para formar un cicloalquilo o heterociclilo de tres a ocho miembros; donde cada uno de dichos alquilo, arilo, heteroarilo, cicloalquilo o heterociclilo pueden estar no sustituidos o estar sustituidos en forma opcional e independiente con uno o más restos seleccionados del grupo formado por: hidroxi, alcoxi, ariloxi, tio, alquiltio, ariltio, amino, amido, alquilamino, arilamino, alquilsulfonilo, arilsulfonilo, sulfonamido, alquilsulfonamido, arilsulfonamido, alquilo, arilo, heteroarilo, ceto, carboxi, carbalcoxi, carboxamido, alcoxicarbonilamino, alcoxicarboniloxi, alquilureido, arilureido, halo, ciano y nitro.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54867004P | 2004-02-27 | 2004-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048241A1 true AR048241A1 (es) | 2006-04-12 |
Family
ID=34961556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100679A AR048241A1 (es) | 2004-02-27 | 2005-02-24 | Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c . |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8067379B2 (es) |
| EP (1) | EP1730110B9 (es) |
| JP (1) | JP4714732B2 (es) |
| KR (2) | KR101316137B1 (es) |
| CN (2) | CN103102389A (es) |
| AR (1) | AR048241A1 (es) |
| AT (1) | ATE470660T1 (es) |
| AU (1) | AU2005222060A1 (es) |
| BR (1) | BRPI0508085A (es) |
| CA (1) | CA2557495C (es) |
| CY (1) | CY1111212T1 (es) |
| DE (1) | DE602005021760D1 (es) |
| DK (1) | DK1730110T3 (es) |
| EC (1) | ECSP066791A (es) |
| ES (1) | ES2346233T3 (es) |
| HK (1) | HK1095819A1 (es) |
| HR (1) | HRP20100416T1 (es) |
| IL (1) | IL177544A (es) |
| MY (1) | MY145081A (es) |
| NO (1) | NO20064358L (es) |
| NZ (1) | NZ549223A (es) |
| PE (1) | PE20051150A1 (es) |
| PL (1) | PL1730110T3 (es) |
| PT (1) | PT1730110E (es) |
| RS (1) | RS51394B (es) |
| RU (1) | RU2428428C9 (es) |
| SG (1) | SG186041A1 (es) |
| SI (1) | SI1730110T1 (es) |
| TW (2) | TWI393704B (es) |
| WO (1) | WO2005087731A1 (es) |
| ZA (1) | ZA200607096B (es) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227742B1 (en) | 1996-10-18 | 2012-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| US7816326B2 (en) * | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
| PT1730110E (pt) * | 2004-02-27 | 2010-09-14 | Schering Corp | Compostos de enxofre como inibidores de serina-protease ns3 do vírus da hepatite c |
| GB0426661D0 (en) * | 2004-12-06 | 2005-01-05 | Isis Innovation | Pyrrolidine compounds |
| WO2006130666A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
| WO2006130686A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors in combination with food |
| BRPI0610737A2 (pt) * | 2005-06-02 | 2010-07-20 | Schering Corp | formulações farmacêuticas e métodos de tratamento usando as mesmas |
| US20060276407A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
| CA2611145A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
| US20060275366A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
| WO2006130626A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
| WO2006130687A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor |
| WO2006130552A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| CA2644389A1 (en) * | 2006-03-03 | 2007-09-20 | Schering Corporation | Pharmaceutical combinations of hcv-protease and -ires inhibitors |
| AU2007227580A1 (en) | 2006-03-16 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for preparing steric compounds |
| WO2007111866A2 (en) * | 2006-03-23 | 2007-10-04 | Schering Corporation | Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto |
| RU2448976C2 (ru) | 2006-04-11 | 2012-04-27 | Новартис Аг | Ингибиторы hcv/вич и их применение |
| DE102006059317A1 (de) | 2006-07-04 | 2008-01-10 | Evonik Degussa Gmbh | Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden |
| CN101506167A (zh) | 2006-08-17 | 2009-08-12 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| US20100081672A1 (en) * | 2006-12-07 | 2010-04-01 | Schering Corporation | Ph sensitive matrix formulation |
| AU2007339382B2 (en) | 2006-12-22 | 2013-05-02 | Merck Sharp & Dohme Llc | 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections |
| WO2008078563A1 (ja) * | 2006-12-22 | 2008-07-03 | Sumitomo Seika Chemicals Co., Ltd. | ３－ベンジルオキシベンゼンチオールの製造方法 |
| JP5211068B2 (ja) | 2006-12-22 | 2013-06-12 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体 |
| JP5055377B2 (ja) | 2006-12-22 | 2012-10-24 | シェーリング コーポレイション | ［５，６−環］環形成インドール誘導体およびその使用方法 |
| CA2693997C (en) | 2007-08-03 | 2013-01-15 | Pierre L. Beaulieu | Viral polymerase inhibitors |
| WO2009032124A1 (en) | 2007-08-29 | 2009-03-12 | Schering Corporation | Substituted indole derivatives and methods of use thereof |
| US8143305B2 (en) | 2007-08-29 | 2012-03-27 | Schering Corporation | 2,3-substituted indole derivatives for treating viral infections |
| CN101842374A (zh) | 2007-08-29 | 2010-09-22 | 先灵公司 | 用于治疗病毒感染的2，3-取代的氮杂吲哚衍生物 |
| JP2010539165A (ja) | 2007-09-14 | 2010-12-16 | シェーリング コーポレイション | Ｃ型肝炎患者を処置する方法 |
| AR068756A1 (es) | 2007-10-10 | 2009-12-02 | Novartis Ag | Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c |
| WO2009064848A1 (en) | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-heterocyclic substituted indole derivatives and methods of use thereof |
| JP5416708B2 (ja) | 2007-11-16 | 2014-02-12 | メルク・シャープ・アンド・ドーム・コーポレーション | ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法 |
| WO2009076747A1 (en) | 2007-12-19 | 2009-06-25 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7964560B2 (en) * | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2727620A1 (en) | 2008-06-13 | 2009-12-17 | Schering Corporation | Tricyclic indole derivatives and methods of use thereof |
| US20110207660A1 (en) * | 2008-08-07 | 2011-08-25 | Schering Corporation | Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion |
| US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| AR074582A1 (es) | 2008-12-12 | 2011-01-26 | Schering Corp | Compuestos deuterados como inhibidores del virus de la hepatitis c (hcv) |
| RU2011127080A (ru) | 2009-01-07 | 2013-02-20 | Сайнексис, Инк. | Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| AU2010253791A1 (en) | 2009-05-29 | 2011-11-24 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C |
| IN2012DN00346A (es) | 2009-07-29 | 2015-05-08 | Schering Corp | |
| AU2010324871A1 (en) | 2009-11-25 | 2012-06-14 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
| SG183526A1 (en) | 2010-03-09 | 2012-09-27 | Merck Sharp & Dohme | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| US20140377223A1 (en) | 2010-07-26 | 2014-12-25 | Joseph A. Kozlowski | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| US9133116B2 (en) | 2010-09-28 | 2015-09-15 | Panacea Biotec Ltd. | Bicyclic compounds |
| US9254292B2 (en) | 2010-09-29 | 2016-02-09 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| WO2012073249A1 (en) | 2010-12-01 | 2012-06-07 | Arch Pharmalabs Limited | A novel process for the preparation of 3-(benzyloxy)- benzenethiol, a key intermediate for the preparation of pharmaceutical drugs. |
| EA201391519A1 (ru) | 2011-04-13 | 2014-03-31 | Мерк Шарп И Доум Корп. | 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний |
| EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
| WO2013039876A1 (en) | 2011-09-14 | 2013-03-21 | Merck Sharp & Dohme Corp. | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| EP3063140A4 (en) | 2013-10-30 | 2017-11-08 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
| WO2017059446A1 (en) * | 2015-10-01 | 2017-04-06 | Memorial Sloan-Kettering Cancer Center | Anthranilyl-adenosinemonosulfamate analogs and uses thereof |
| EP3356447A4 (en) * | 2015-10-01 | 2019-06-12 | Memorial Sloan-Kettering Cancer Center | INHIBITORS OF MENACHINONE BIOSYNTHESIS |
| MX2018016102A (es) * | 2016-06-21 | 2019-08-29 | Orion Ophthalmology LLC | Derivados alifaticos de prolinamida. |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL169273B1 (pl) | 1990-04-04 | 1996-06-28 | Chiron Corp | skierowanej przeciw wirusowi zapalenia watroby C PL |
| US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
| HU227742B1 (en) | 1996-10-18 | 2012-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| JP4452401B2 (ja) | 1997-08-11 | 2010-04-21 | ベーリンガー インゲルハイム （カナダ） リミテッド | Ｃ型肝炎ウイルス阻害ペプチドアナログ |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| AU2001251165A1 (en) | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| ES2317900T3 (es) | 2000-04-05 | 2009-05-01 | Schering Corporation | Inhibidores de serina proteasa ns3 macrociclicos del virus de la hepatitis c que comprenden fragmentos n-ciclicas p2. |
| CN1432022A (zh) | 2000-04-19 | 2003-07-23 | 先灵公司 | 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂 |
| WO2002008251A2 (en) | 2000-07-21 | 2002-01-31 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| HUP0303358A3 (en) | 2000-07-21 | 2005-10-28 | Schering Corp | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them |
| KR100904788B1 (ko) * | 2000-07-21 | 2009-06-25 | 쉐링 코포레이션 | Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드 |
| US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| KR20030091946A (ko) | 2000-12-12 | 2003-12-03 | 쉐링 코포레이션 | Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 디아릴 펩티드 |
| US7816326B2 (en) | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
| PT1730110E (pt) | 2004-02-27 | 2010-09-14 | Schering Corp | Compostos de enxofre como inibidores de serina-protease ns3 do vírus da hepatite c |
| BRPI0610737A2 (pt) | 2005-06-02 | 2010-07-20 | Schering Corp | formulações farmacêuticas e métodos de tratamento usando as mesmas |
-
2005
- 2005-02-24 PT PT05723607T patent/PT1730110E/pt unknown
- 2005-02-24 RS RSP-2010/0360A patent/RS51394B/en unknown
- 2005-02-24 KR KR1020067017257A patent/KR101316137B1/ko not_active IP Right Cessation
- 2005-02-24 PL PL05723607T patent/PL1730110T3/pl unknown
- 2005-02-24 US US11/064,673 patent/US8067379B2/en active Active
- 2005-02-24 MY MYPI20050737A patent/MY145081A/en unknown
- 2005-02-24 AR ARP050100679A patent/AR048241A1/es not_active Application Discontinuation
- 2005-02-24 AT AT05723607T patent/ATE470660T1/de active
- 2005-02-24 AU AU2005222060A patent/AU2005222060A1/en not_active Abandoned
- 2005-02-24 BR BRPI0508085-1A patent/BRPI0508085A/pt not_active IP Right Cessation
- 2005-02-24 DK DK05723607.7T patent/DK1730110T3/da active
- 2005-02-24 WO PCT/US2005/005795 patent/WO2005087731A1/en active Application Filing
- 2005-02-24 NZ NZ549223A patent/NZ549223A/en not_active IP Right Cessation
- 2005-02-24 CA CA2557495A patent/CA2557495C/en not_active Expired - Fee Related
- 2005-02-24 TW TW098107879A patent/TWI393704B/zh not_active IP Right Cessation
- 2005-02-24 CN CN2012103533032A patent/CN103102389A/zh active Pending
- 2005-02-24 SI SI200531086T patent/SI1730110T1/sl unknown
- 2005-02-24 ES ES05723607T patent/ES2346233T3/es active Active
- 2005-02-24 EP EP05723607A patent/EP1730110B9/en active Active
- 2005-02-24 RU RU2006134003/04A patent/RU2428428C9/ru active
- 2005-02-24 CN CNA2005800128593A patent/CN101076516A/zh active Pending
- 2005-02-24 JP JP2007500955A patent/JP4714732B2/ja not_active Expired - Fee Related
- 2005-02-24 TW TW094105518A patent/TWI314927B/zh not_active IP Right Cessation
- 2005-02-24 KR KR1020127034290A patent/KR20130018418A/ko not_active Application Discontinuation
- 2005-02-24 PE PE2005000220A patent/PE20051150A1/es not_active Application Discontinuation
- 2005-02-24 DE DE602005021760T patent/DE602005021760D1/de active Active
- 2005-02-24 SG SG2012087664A patent/SG186041A1/en unknown
-
2006
- 2006-08-17 IL IL177544A patent/IL177544A/en not_active IP Right Cessation
- 2006-08-24 ZA ZA200607096A patent/ZA200607096B/xx unknown
- 2006-08-25 EC EC2006006791A patent/ECSP066791A/es unknown
- 2006-09-26 NO NO20064358A patent/NO20064358L/no not_active Application Discontinuation
-
2007
- 2007-03-19 HK HK07102951.6A patent/HK1095819A1/xx not_active IP Right Cessation
-
2010
- 2010-07-27 HR HR20100416T patent/HRP20100416T1/hr unknown
- 2010-09-01 CY CY20101100796T patent/CY1111212T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048241A1 (es) | Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c . | |
| AR047903A1 (es) | Compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
| AR047901A1 (es) | Inhibidores de proteasa ns3 del virus de la hepatitis c | |
| AR048023A1 (es) | Cetoamidas con p4 ciclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
| AR047902A1 (es) | Compuestos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
| AR048413A1 (es) | Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
| AR046758A1 (es) | Inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c | |
| AR055198A1 (es) | Formulaciones farmaceuticas y metodos de tratamiento que las utilizan | |
| AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR054197A1 (es) | Medicamentos y metodos combinando un inhibidor de la proteasa hcv y un competidor akr | |
| AR038183A1 (es) | Peptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c | |
| AR064547A1 (es) | Derivados de azaspiro como antagonistas del receptor v1a | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR060003A1 (es) | Combinaciones del(de los) inhibidor(es) de la proteasa del virus de la hepatitis c e inhibidor(es) de cyp3a4, y metodos para el tratamiento relacionados a este (estos) | |
| AR045938A1 (es) | Peptidos macrociclicos activos contra el virus de la hepatitis c | |
| AR030249A1 (es) | Peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c, composicion farmaceutica que lo comprende, un metodo para su preparacion y el uso de los mismos para la manufactura de medicamentos y un metodo para modular el procesamiento de un polipeptido del virus | |
| AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| AR038214A1 (es) | Compuestos de prolina como inhibidores de la serina proteasa ns3 del virus de la hepatitis c | |
| AR039203A1 (es) | Derivados de quinazolina | |
| AR056195A1 (es) | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos | |
| AR038172A1 (es) | Compuesto de ciclohexano y ciclohexeno, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica, procedimiento para preparar el compuesto y compuestos intermediarios en dicho procedimiento | |
| AR059429A1 (es) | Combinaciones que involucran el (los) inhibidor(es) de la protesa hcv y metodos de tratamiento relacionados al (los) mismo (s) | |
| AR054612A1 (es) | Derivados de espiroquetas y composiciones farmaceuticas para su utilizacion como agente terapeutico para diabetes | |
| AR040336A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto | |
| AR056838A1 (es) | Derivados de 1,2,5-tiadiazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |